Answers are grounded in this paper and cite their sources.
A tremendous level of interest has surrounded the field of immunostimulatory oligonucleotides (IS-ODNs) over recent years, fueled by promising results from preclinical and clinical studies in malignant, infectious and autoimmune diseases. Despite these results, clinical utility of free ODNs is faced with several significant challenges, including poor in vivo stability, acute adverse side effects, unfavorable pharmacokinetic and biodistribution profiles and poor cellular uptake characteristics. For these reasons, there has been considerable interest in the development of liposomal delivery strategies for IS-ODNs. This review provides a brief overview of IS-ODNs, their mechanism of action and the preclinical and clinical studies supporting its potential as an immunotherapeutic agent. Furthermore, it outlines problems associated with the clinical utility of free ODNs and the solutions offered by liposomal encapsulation. Finally, effects of liposomal delivery on IS-ODN immunopotency and prophylactic and therapeutic activity in disease models are discussed.
No takes yet. Share an insight, caveat, or question.
Ying K. Tam (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: